Form 4: Aprea Therapeutics Director Equity Grant Disclosure
Statement of Changes in Beneficial Ownership
Director Jean-Pierre Bizzari received a grant of restricted stock units and stock options as part of board compensation.
Summary
- Director Jean-Pierre Bizzari was granted 3,135 restricted stock units (RSUs) on June 16, 2026.
- The director also received an option to purchase 12,555 shares of common stock at an exercise price of $0.7293 per share.
- Both the RSUs and the stock options are scheduled to vest in full on June 16, 2027, contingent upon continued service on the board.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant change in company strategy or financial outlook.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Standard retention mechanism for board members.
Negatives
- Dilutive impact of new equity grants on existing shareholders.
Risks
- Potential for future dilution if additional equity grants are issued to board members or employees.
- Dependence on continued service for vesting of equity awards.
Future Outlook
The equity grants are subject to continued service on the board through June 16, 2027, at which point they will vest.
Industry Context
StockSavvy.ai notes that equity-based compensation for board members is a standard practice in the biotechnology sector to ensure long-term alignment between directors and shareholders, particularly for companies in the development stage.
Comparison to Industry Standards
- The use of time-based vesting for director equity is consistent with standard corporate governance practices for small-cap biotech firms.
- The grant size is typical for non-executive director compensation packages in the industry.
Stakeholder Impact
- Minor dilution for existing shareholders due to the issuance of new equity.
Next Steps
- Vesting of equity awards on June 16, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/16/2026 | Date of grant for restricted stock units and stock options. |
| 06/17/2026 | Date of filing for the Form 4. |
| 06/16/2027 | Vesting date for both the restricted stock units and the stock options. |
| 06/16/2036 | Expiration date for the stock options. |
Keywords
Aprea Therapeutics, APRE, Form 4, Director Compensation, Equity Grant, Insider Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.